CLINICAL TRIALS PROFILE FOR ARIMOCLOMOL CITRATE
✉ Email this page to a colleague
All Clinical Trials for ARIMOCLOMOL CITRATE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03491462 ↗ | Arimoclomol in Amyotropic Lateral Sclerosis | Completed | Orphazyme | Phase 3 | 2018-07-31 | A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS) |
NCT03836716 ↗ | Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial | Terminated | Orphazyme | Phase 3 | 2019-09-19 | A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS)who have completed the ORARIALS-01 trial. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ARIMOCLOMOL CITRATE
Condition Name
Clinical Trial Locations for ARIMOCLOMOL CITRATE
Trials by Country
Clinical Trial Progress for ARIMOCLOMOL CITRATE
Clinical Trial Phase
Clinical Trial Sponsors for ARIMOCLOMOL CITRATE
Sponsor Name